Eledon Pharmaceuticals Inc Total Liabilities
Eledon Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Eledon Pharmaceuticals Inc (ELDN) has total liabilities worth $100.82 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Eledon Pharmaceuticals Inc (ELDN) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Eledon Pharmaceuticals Inc (2012–2025)
Total liabilities of Eledon Pharmaceuticals Inc from 2012 to 2025. This chart illustrates how Eledon Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Eledon Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Eledon Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chargeurs S.A.
PA:CRI
|
France | €702.90 Million |
|
Xinjiang Zhundong Petroleum
SHE:002207
|
China | CN¥314.40 Million |
|
AME REIT
KLSE:5307
|
Malaysia | RM218.05 Million |
|
Great China Metal Industry Co Ltd
TW:9905
|
Taiwan | NT$3.49 Billion |
|
Prodia Widyahusada Tbk PT
JK:PRDA
|
Indonesia | Rp261.44 Billion |
|
Nova Lifestyle I
NASDAQ:NVFY
|
USA | $4.70 Million |
|
Astarta Holding N.V.
WAR:AST
|
Poland | zł254.64 Million |
|
PT Multikarya Asia Pacific Ray
JK:MKAP
|
Indonesia | Rp169.19 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Eledon Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Eledon Pharmaceuticals Inc (ELDN) total assets.
Liquidity & Leverage Metrics
Eledon Pharmaceuticals Inc Total Liabilities Ratios Explained
Eledon Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eledon Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eledon Pharmaceuticals Inc (2012–2025)
The table below shows the annual total liabilities of Eledon Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $100.82 Million | +70.12% |
| 2024-12-31 | $59.27 Million | +39.53% |
| 2023-12-31 | $42.48 Million | +393.32% |
| 2022-12-31 | $8.61 Million | +31.39% |
| 2021-12-31 | $6.55 Million | -0.55% |
| 2020-12-31 | $6.59 Million | +349.45% |
| 2019-12-31 | $1.47 Million | -42.15% |
| 2018-12-31 | $2.53 Million | +75.97% |
| 2017-12-31 | $1.44 Million | -50.40% |
| 2016-12-31 | $2.90 Million | -53.55% |
| 2015-12-31 | $6.25 Million | +47.30% |
| 2014-12-31 | $4.24 Million | -95.15% |
| 2013-12-31 | $87.55 Million | +68.82% |
| 2012-12-31 | $51.86 Million | -- |
About Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for C… Read more